Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Horizon Therapeutics Ireland DAC, 70 St. Stephens Green, Dublin 2, D02 E2X4, Ireland
Uplizna 100 mg concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to slightly yellow solution. The solution has a pH of approximately 6.0 and an osmolality of approximately 280 mOsm/kg. |
Each vial contains 100 mg of inebilizumab in 10 mL at a concentration of 10 mg/mL. The final concentration after dilution is 1.0 mg/mL.
Inebilizumab is a humanised monoclonal antibody produced in Chinese hamster ovary cell line by recombinant DNA technology.
Excipient with known effect: This medicinal product contains 16.1 mg of sodium per vial.
For the full list of excipients, see section 6.1.
| List of Excipients |
|---|
|
Histidine |
10 mL of concentrate in a Type 1 glass vial with an elastomeric stopper and a mist gray flip-off aluminium seal.
Pack size of 3 vials.
Horizon Therapeutics Ireland DAC, 70 St. Stephen’s Green, Dublin 2, D02 E2X4, Ireland
EU/1/21/1602/001
Date of first authorisation: 25 April 2022
| Drug | Countries | |
|---|---|---|
| UPLIZNA | Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Japan, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
